Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(9%)
Results Posted
0%(0 trials)
Terminated
1(9%)

Phase Distribution

Ph early_phase_1
1
9%
Ph phase_3
2
18%
Ph phase_2
2
18%
Ph phase_4
2
18%
Ph phase_1
4
36%

Phase Distribution

5

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)
Other(4)

Detailed Status

unknown4
Completed4
Recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (9.1%)
Phase 14 (36.4%)
Phase 22 (18.2%)
Phase 32 (18.2%)
Phase 42 (18.2%)

Trials by Status

recruiting19%
not_yet_recruiting19%
terminated19%
unknown436%
completed436%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_2

Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA

NCT07400341
completedphase_4

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

NCT02267993
not_yet_recruitingphase_3

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

NCT06440824
unknownphase_4

Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients

NCT05217719
unknownearly_phase_1

The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

NCT03673215
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07400341Phase 2

Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA

Recruiting
NCT02267993Phase 4

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Completed
NCT06440824Phase 3

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

Not Yet Recruiting
NCT05217719Phase 4

Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients

Unknown
NCT03673215Early Phase 1

The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

Unknown
NCT03014102Phase 1

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Unknown
NCT03492515Phase 3

Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

Unknown
NCT01319669Phase 2

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

Terminated
NCT00003597Phase 1

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Completed
NCT00006225Phase 1

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Completed
NCT00187109Phase 1

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11